Choon Kee Lee

Summary

Affiliation: University of Arkansas for Medical Sciences
Country: USA

Publications

  1. ncbi request reprint Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning
    Choon Kee Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Exp Hematol 31:73-80. 2003
  2. ncbi request reprint DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma
    Choon Kee Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Slot 776, 4301 West Markham, Little Rock, AR 72205, USA
    J Clin Oncol 21:2732-9. 2003
  3. ncbi request reprint Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival
    Maurizio Zangari
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Clin Lymphoma 4:32-5. 2003
  4. ncbi request reprint Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 118:1041-7. 2002
  5. ncbi request reprint Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation
    Maurizio Zangari
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA
    Br J Haematol 126:715-21. 2004
  6. ncbi request reprint Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 123:484-9. 2003
  7. ncbi request reprint Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma
    Maurizio Zangari
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 131:71-3. 2005
  8. ncbi request reprint Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds
    Elias J Anaissie
    Myeloma Institute for Research and Treatment, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Clin Infect Dis 35:E86-8. 2002

Collaborators

Detail Information

Publications8

  1. ncbi request reprint Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning
    Choon Kee Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Exp Hematol 31:73-80. 2003
    ..The aim of this study was to identify prognostic factors for outcome of high-risk patients with multiple myeloma after allogeneic transplantation prepared by reduced intensity conditioning (RIC)...
  2. ncbi request reprint DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma
    Choon Kee Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Slot 776, 4301 West Markham, Little Rock, AR 72205, USA
    J Clin Oncol 21:2732-9. 2003
    ..To improve outcome in previously treated patients (at least two cycles of standard therapy) with multiple myeloma, thalidomide was combined with cytotoxic chemotherapy as induction therapy...
  3. ncbi request reprint Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival
    Maurizio Zangari
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Clin Lymphoma 4:32-5. 2003
    ..002), and creatinine level > or = 2 mg/dL (P < 0.001). However, the development of DVT did not adversely affect survival when examined as a time-dependent variable and adjusted for standard risk features (hazard ratio, 0.8; P = 0.162)...
  4. ncbi request reprint Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 118:1041-7. 2002
    ..Furthermore, these parameters in combination with easily obtained pretransplant levels of beta-2 microglobulin and albumin define three groups of MM patients with clearly distinct outcomes...
  5. ncbi request reprint Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation
    Maurizio Zangari
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA
    Br J Haematol 126:715-21. 2004
    ..The rate of DVT recurrence observed in our study upon thalidomide resumption was sufficiently low to allow its continuation in patients who may benefit from this therapeutic intervention...
  6. ncbi request reprint Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 123:484-9. 2003
    ..In conclusion, a sizeable fraction of myeloma patients relapsing after tandem autotransplants without poor-risk features enjoyed meaningful survival prolongation when appropriately treated...
  7. ncbi request reprint Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma
    Maurizio Zangari
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 131:71-3. 2005
    ..The rise in ALP after bortezomib in three patients was explained by a parallel increase in bone-specific ALP and parathyroid hormone, suggesting that response to bortezomib in myeloma is closely associated with osteoblastic activation...
  8. ncbi request reprint Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds
    Elias J Anaissie
    Myeloma Institute for Research and Treatment, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Clin Infect Dis 35:E86-8. 2002
    ..In this report, we show that cleaning the floors of patient shower facilities in a bone marrow transplantation unit reduced the mean air concentrations of molds, including Aspergillus species (from 12 cfu/m3 to 4 cfu/m3; P=.0047)...